Abstract
Background Vitamin D is a fundamental regulator of host defences by activating genes related to innate and adaptive immunity. Previous research shows a correlation between the levels of vitamin D in patients infected with SARS-CoV-2 and the degree of disease severity. This work investigates the impact of the genetic background related to vitamin D pathways on COVID-19 severity. For the first time, the Portuguese population was characterized regarding the prevalence of high impact variants in genes associated with the vitamin D pathways.
Methods This study enrolled 517 patients admitted to two tertiary Portuguese hospitals. The serum concentration of 25 (OH)D, was measured in the hospital at the time of patient admission. Genetic variants, 18 variants, in the genes AMDHD1, CYP2R1, CYP24A1, DHCR7, GC, SEC23A, and VDR were analysed.
Results The results show that polymorphisms in the vitamin D binding protein encoded by the GC gene are related to the infection severity (p = 0.005). There is an association between vitamin D polygenic risk score and the serum concentration of 25 (OH)D (p = 0.042). There is an association between 25 (OH)D levels and the survival and fatal outcomes (p = 1.5e-4). The Portuguese population has a higher prevalence of the DHCR7 RS12785878 variant when compared with its prevalence in the European population (19% versus 10%).
Conclusion This study shows a genetic susceptibility for vitamin D deficiency that might explain higher severity degrees in COVID-19 patients. These results reinforce the relevance of personalized strategies in the context of viral diseases.
Trial registration NCT04370808
Competing Interest Statement
All authors affiliated with the company HeartGenetics, Genetics and Biotechnology SA, declare that the company developed a genetic test, the MyVitDGenes, that was used to evaluate all the polymorphisms under analysis in this work. All other authors have declared that no conflict of interest exists.
Clinical Trial
NCT04370808
Funding Statement
We thank all the study participants, who donated blood and authorized the genetic analysis and the collection of the clinical and phenotypic personal data. This project was supported by the Fundacao para a Ciencia e Tecnologia, program Research 4 Covid-19 Apoio especial a projetos de implementacao rapida para solucoes inovadoras de resposta a pandemia de COVID-19.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Ethics Committee of Hospital de Santa Maria in Lisbon and Hospital de Sao Joao in Oporto. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and followed the Good Clinical Practice guidelines. Written informed consent was obtained from all study participants prior to their inclusion in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For the moment the data used in this project is just available to all participant institutions. Clinical history, genotypic and phenotypic data, stored at the e-CRF, were collected and managed using REDCap electronic data capture tools hosted by BioData.pt (https://biodata.pt/), the Portuguese distributed infrastructure for biological data, at INESC-ID research institute. All datasets are pseudo-anonymous and only one of them has a key that connects to the patient. In accordance with the GDPR, only the PI of the project (Prof. Fausto Pinto) and the clinicians responsible for data acquisition have access to this key. All project participants have controlled data access. The clinical history and the patient informed consent were supervised by the Cardiology Service at Santa Maria hospital and by the Pathology Service at Sao Joao hospital.
